Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and CKD. AGI,alpha-glucosidase inhibitor: ASCVD. atherosclerotic cardiovascular disease: CKD. chronic kidney disease, DPP4i, dipeptidyl peptidase—4 inhibitor, eGFR. estimated glomerular filtration rate GLP IRA. glucagon-like peptide- I receptor agonist SGLT2i. sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea; T2D. type 2 diabetes; TZD, thiazolidinedione. type 2 diabetes; TZD, #KDIGO2020 #CKD #Diabetes Management in CKD #management #treatment #CHART
